Overview

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

Status:
Completed
Trial end date:
2021-08-28
Target enrollment:
0
Participant gender:
All
Summary
This is a Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 monotherapy or in combination with AMG 404 in Subjects with Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII). This is a first in human (FIH), open-label, sequential-dose-escalation study in subjects with EGFRvIII-positive glioblastoma or malignant glioma. This study will enroll 2 groups of subjects according to disease stage, recurrent disease (Group 1) and maintenance treatment after SoC in newly diagnosed disease (Group 2).
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Amgen
Criteria
Inclusion Criteria

- Eastern Cooperative Oncology Group (ECOG, Appendix G) Performance Status of less than
or equal to 1

- Life expectancy of at least 3 months, in the opinion of the investigator.

- Must have pathologically documented, and definitively diagnosed World Health
Organization (WHO) grade 4, glioblastoma or lower grade malignant gliomas with
EGFRvIII positive tumor

- Must have recurrent disease confirmed by MRI (Group 1) or completed SoC therapy such
as surgery with adjuvant radiochemotherapy with or without maintenance temozolomide
according to local standards for newly diagnosed disease (Group 2)

- Hematological function as follows:

- Absolute neutrophil count (ANC) greater than 1500/mm3 (1.5 × 10 9/L)

- Platelet count greater than 100,000 mm3 (100 × 10 9/L)

- White blood cell (WBC) count greater than 3 × 10 9/L

- Hemoglobin greater than 9.0 g/dL

- Renal function as follows: serum creatinine less than 2.0 mg/dL and estimated
glomerular filtration rate greater than or equal to 60 mL/min/1.73 m2 by MDRD and
urine protein quantitative value of less than 30 mg/dL in urinalysis or less than or
equal to 1+ on dipstick

- Hepatic function as follows:

- Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) less than or
equal to 3.0 x upper limit of normal (ULN)

- Bilirubin less than or equal to 1.5 x ULN (unless considered due to Gilbert's
syndrome or hemolysis)

Exclusion Criteria

- History or evidence of central nervous system bleeding as defined by stroke or
intraocular bleed (including embolic stroke) not associated with any antitumor surgery
within 6 months before enrolment

- Known hypersensitivity to immunoglobulins or to any other component of the IP
formulation

- Active infection requiring intravenous antibiotics that was completed less than 1 week
of study enrolment (day 1) with the exemption of prophylactic antibiotics for long
line insertion or biopsy

- Known positive test for human immunodeficiency virus (HIV)

- Active hepatitis B and C based on the following results:

- Positive for hepatitis B surface antigen (HepBsAg) (indicative of chronic
hepatitis B or recent acute hepatitis B)

- Negative HepBsAg and positive for hepatitis B core antibody: hepatitis B virus
DNA by polymerase chain reaction (PCR) is necessary. Detectable hepatitis B virus
DNA suggests occult hepatitis B

- Positive hepatitis C virus antibody (HepCAb): hepatitis C virus RNA by PCR is
necessary. Detectable hepatitis C virus RNA suggests chronic hepatitis C

- Unresolved toxicities from prior antitumor therapy, defined as not having resolved to
CTCAE, version 4.0 grade 1 (with the exception of myelosuppression, eg, neutropenia,
anemia, thrombocytopenia), or to levels dictated in the eligibility criteria with the
exception of alopecia or toxicities from prior antitumor therapy that are considered
irreversible (defined as having been present and stable for greater than 2 months)
which may be allowed if they are not otherwise described in the exclusion criteria AND
there is agreement to allow by both the investigator and sponsor

- Antitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy, or
investigational agent) within 14 days (Group 2 subjects) or 5 half-lives (whichever is
longer: for Group 1 subjects) of day 1. Avastin, Pembrolizumab must be stopped 14 days
prior to day 1

- Female with a positive pregnancy test.